NEW YORK (GenomeWeb News) – Genomic Health said Tuesday after the close of the market that sales for its flagship product, the Oncotype Dx breast cancer assay, swelled 81 percent for the second quarter ended June 30, 2008, and the firm cut its net loss 43 percent year over year.
 
Genomic Health reported total revenues of $27.8 million, up 89.1 percent from revenues of $14.7 million in the second quarter of 2007.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York Times reports that evidence linking trauma in one generation to epigenetic effects that influence subsequent generations may be overstated.

In PNAS this week: skin pigmentation evolution among KhoeSan, biomarkers for dengue virus progression, and more.

The New York Times and ProPublica say that many physicians fail to disclose their financial ties when publishing in medical journals.

The Wall Street Journal reports Human Longevity's valuation has dropped by 80 percent.